These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 19707263)

  • 1. Finasteride in the treatment of patients with benign prostatic hyperplasia: a review.
    Smith AB; Carson CC
    Ther Clin Risk Manag; 2009 Jun; 5(3):535-45. PubMed ID: 19707263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
    Logan YT; Belgeri MT
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.
    Marberger M
    Nat Clin Pract Urol; 2006 Sep; 3(9):495-503. PubMed ID: 16964191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ; Miner M
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia.
    Tarter TH; Vaughan ED
    Curr Pharm Des; 2006; 12(7):775-83. PubMed ID: 16515494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia.
    Kim EH; Brockman JA; Andriole GL
    Asian J Urol; 2018 Jan; 5(1):28-32. PubMed ID: 29379733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized medicine for the management of benign prostatic hyperplasia.
    Bechis SK; Otsetov AG; Ge R; Olumi AF
    J Urol; 2014 Jul; 192(1):16-23. PubMed ID: 24582540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
    Pinto F; Racioppi M; Sacco E; Totaro A; Brescia A; Volpe A; Gardi M; Bassi PF
    Arch Ital Urol Androl; 2009 Mar; 81(1):1-8. PubMed ID: 19499750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benign prostatic hyperplasia progression and its impact on treatment.
    Djavan B; Waldert M; Ghawidel C; Marberger M
    Curr Opin Urol; 2004 Jan; 14(1):45-50. PubMed ID: 15091050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group.
    Marberger MJ
    Urology; 1998 May; 51(5):677-86. PubMed ID: 9610579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
    Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM
    BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Landmark studies impacting the medical management of benign prostatic hyperplasia.
    Lepor H
    Rev Urol; 2003; 5 Suppl 5(Suppl 5):S28-35. PubMed ID: 16985967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Landmark studies impacting the medical management of benign prostatic hyperplasia.
    Lepor H
    Rev Urol; 2003; 5 Suppl 4(Suppl 4):S34-41. PubMed ID: 16985962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of combination therapy in patients with benign prostatic hyperplasia.
    McVary KT
    Clin Ther; 2007 Mar; 29(3):387-98. PubMed ID: 17577460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications.
    O'Leary MP
    Urology; 2003 Sep; 62(3 Suppl 1):15-23. PubMed ID: 12957196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia.
    Kaplan SA; Holtgrewe HL; Bruskewitz R; Saltzman B; Mobley D; Narayan P; Lund RH; Weiner S; Wells G; Cook TJ; Meehan A; Waldstreicher J;
    Urology; 2001 Jun; 57(6):1073-7. PubMed ID: 11377309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.
    Emberton M; Zinner N; Michel MC; Gittelman M; Chung MK; Madersbacher S
    BJU Int; 2007 Aug; 100(2):249-53. PubMed ID: 17617135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.